Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
AMGNAmgen Inc. | +0.18% | 15.88 |
AZNAstraZeneca PLC ADR | +0.14% | 25.38 |
GSKGlaxoSmithKline PLC ADR | +0.19% | 111.02 |
NVSNovartis AG ADR | +2.74% | 28.18 |
ABTAbbott Laboratories | +0.04% | 23.35 |
BMYBristol-Myers Squibb Co. | -0.85% | 72.23 |
JNJJohnson & Johnson | -0.44% | 20.43 |
LLYEli Lilly & Co. | -0.03% | 34.77 |
MRKMerck & Co. Inc. | -0.05% | 33.85 |
MYLMylan N.V. | -0.43% | 26.49 |
Pfizer, Inc. is a research-based, global biopharmaceutical company, which engages in the manufacture of vaccines and injectable biologic medicines. It operates through the following segments: Global Innovative Pharmaceutical, Global Vaccines, Oncology and Consumer Healthcare,...
| Q2 2016 Estimate Trends | |
|---|---|
| Current: | $0.61 |
| 1 month ago: | $0.59 |
| 3 months ago: | $0.59 |
| Q3 2016 Estimate Trends | |
|---|---|
| Current: | $0.62 |
| 1 month ago: | $0.61 |
| 3 months ago: | $0.60 |
| Mar 2016 | 5-quarter trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | +27.30% | | ||||||||
| Sales or Revenue | 13.01 B | | ||||||||
| Sales or Revenue Growth | +19.71% | | ||||||||
| EBITDA | - | | ||||||||
| 2015 | 5-year trend | |||||||||
| Net Income Growth | -23.53% | | ||||||||
| Sales or Revenue | 48.85 B | | ||||||||
| Sales or Revenue Growth | -1.52% | | ||||||||
| EBITDA | +18.45 B | |